

DEVELOPMENT OF SUSTAINED RELEASE MATRIX TABLETS OF CARVEDILOL AND EVALUATION OF POLYMER EFFECT ON *IN- VITRO* RELEASE PATTERN

**Syeda Tahrina Ashkari, Md. Mizanur Rahman Moghal^{*}, Syed Masudur Rahman Dewan,
Mohammad Nurul Amin**

Department of Pharmacy, Noakhali Science and Technology University, Sonapur, Noakhali- 3814, Bangladesh.

ABSTRACT

The present study was designed to evaluate the polymeric effect of METHOCEL K100MCR on the sustained release drug product of Carvedilol, an antihypertensive drug and also used for congestive heart failure. Carvedilol matrix tablets were formulated by direct compression method using METHOCEL K100MCR polymer in various percentage. Physical parameters were tested and the dissolution procedure was performed by using USP paddle method for eight hours to examine the release kinetics. In the study, METHOCEL K100MCR polymer was found to cause the strong retardation of the drug release. The release mechanism was explored and explained with zero order, first order, Higuchi and Korsmeyer equation. Polymer type, polymer level and physicochemical properties of drug functionalize on the release kinetics of sustained release Carvedilol formulation. With a satisfactory result this sustained release Carvedilol drug can be marketed to treat patient ensuring proper healthcare.

Key words: Carvedilol, Sustained release drug, Methocel, Matrix tablet, Formulation, Higuchi equation, Korsmeyer-Peppas.

INTRODUCTION

Sustained drug delivery involves the application of physical and polymer chemistry to produce well characterized and reproducible dosage forms, which control drug entry into the body within the specifications of the required drug delivery profile. In this type of dosage forms, the rate of drug release mainly controlled by the delivery system itself, though it may be influenced by external conditions, like pH, enzymes, ions, motility and physiological conditions [1]. Sustained release tablets and capsules are commonly taken only once or twice daily, compared with counterpart conventional forms that may have to take three or four times daily to achieve the same therapeutic effect [2]. Typically, sustained release products provide an immediate release of drug that promptly produces the desired therapeutic effect, followed by gradual release of additional amounts of drug to maintain

this effect over a predetermined period. The drug release from matrix tablet depends on other factors such as pore permeability, shape and size of matrix, drug solubility, polymer molecular weight, drug loading, compression force, and hydrodynamic conditions [3,4]. Previous studies developed by Williams *et al.* [5] led to the conclusion that the type and level of excipients influence the rate and extension of drug release. Carvedilol is a nonselective beta blocker which is used for treating high blood pressure and mild to moderate congestive heart failure. The aim of our present study was to formulate sustained release matrix tablet of Carvedilol using METHOCEL and evaluate its release profile to validate the formulation.

MATERIALS AND METHODS

Materials

The ingredients and the equipments used in the

formulations are mentioned in Table 1 and Table 2 respectively.

Preparation of matrix tablet-Carvedilol

The tablets of each batch were prepared by direct compression method. In all the formulation the weight of the active ingredient, Carvedilol 6.25 mg and the total weight were adjusted to 180 mg. At first the active ingredient and other excipients and polymer were accurately measured. Blending was then done following proper mixing with uniformity using a mortar. The API matrix forming polymer METHOCEL K100 MCR was then added, after that milling of the mixed ingredient was performed. At last talc, Mg stearate, avicel were added to the formulation. In the formulation technique the compression force was 3.5 ton. 12 mm flat die was used in this tablet formulation.

Evaluation of Tablets

Length, Width, Size and Shape

The length and width of tablets depends on the die and punches selected for making the tablets. The tablets of various sizes and shapes are prepared but generally they are circular with either flat or biconvex faces. Here we prepared round cylindrical shape tablets.

Thickness

The thickness of a tablet can vary without any change in its weight. This is generally due to the difference of density of granules, pressure applied for compression and the speed of compression. The thickness of the tablets was determined by using a Digital Caliper (range 0-150 mm).

Uniformity of Weight

It is desirable that every individual tablet in a batch should be in uniform weight and weight variation within permissible limits. If any weight variation is there, that should fall within the prescribed limits (generally $\pm 10\%$ for tablets weighing 130 mg or less, $\pm 7.5\%$ for tablets weighing 130 to 324 mg and $\pm 5\%$ for tablets weighing more than 324 mg) [6].

The weights of 10 tablets of each batch were taken at individually and calculate the average weight of 10 tablets. The weights were determined by using an electronic balance (Adventurer TM electronic balance, Model AR2140, Capacity (Max) - 210 gm, Readability 0.0001 gm). Then determine the percentage of weight variation of each tablet by using following formula.

Percentage of weight variation = $\{(\text{Average weight} - \text{Individual weight}) / \text{Average wt.}\} \times 100$

Friability

Friability test was performed to evaluate the ability of the tablets to withstand abrasion in packing, handling and transporting. The instrument used for this test

is known as 'Friability Test Apparatus' or 'Friabilator'. It consists of a plastic chamber which is divided into two parts and revolves at a speed of 25 rpm. A number of tablets were weighed (W_1) and placed in the tumbling chamber which was rotated for four minutes or for 100 revolutions. During each revolution the tablets fall from a distance of six inches to undergo shock. After 100 revolutions the tablets were again weighed (W_2) and the loss in weight indicates the friability. The acceptable limits of weights loss should not be more than 1 percent [7].

Friability = $\{(W_1 - W_2) / W_1\} \times 100$

Hardness

The hardness of tablet depends on the weight of the material used, space between the upper and lower punches at the time of compression and pressure applied during compression. The hardness also depends on the nature and quantity of excipients used during compression.

The hardness of the tablets was determined by using a hand operated hardness tester apparatus (Electrolab, EH-01P). A tablet hardness of about 6-8 kg-ft was considered for mechanical stability [6]. If the finished tablet is too hard, it may not disintegrate in the required period of time and if the tablet is too soft it may not withstand the handling during packing and transporting. Therefore it is very necessary to check the hardness of tablets when they are being compressed and pressure adjusted accordingly on the tablet machine.

Assay of Carvedilol

Preparation Sample Solution

180 mg of crushed tablet powder (equivalent to 6.25 mg) was dissolved in 0.1 N HCl solution and made the volume up to 100 ml. The solution was diluted 100 times and absorbance was taken. Then the percentage of potency was calculated by the following equation:

$$\% \text{ of Potency} = \frac{A_{\text{spl}} \times W_{\text{std}} \times P_{\text{std}} \times \text{Average weight}}{A_{\text{std}} \times W_{\text{spl}} \times \text{Label claimed value}}$$

Where,

A_{spl} = Absorbance of Sample

W_{std} = Weight of Standard

P_{std} = Potency of standard

A_{std} = Absorbance of standard

W_{spl} = Weight of sample

In-Vitro Release Studies

900 ml of 0.1 N HCl was placed into dissolution vessels and the temperature was set to 37⁰ C. Tablets were transferred to each vessel. Basket was immersed in media. At the end of 30 minutes 5ml samples were withdrawn from each vessel. The withdrawn quantity of samples was replaced by the same. The absorbance was measured at 241 nm by an UV spectrophotometer (UV-1800, Shimadzu, Japan) using 0.1 N HCl as blank. At every 30 minutes

interval 5ml samples were withdrawn from the dissolution vessel and replaced with fresh dissolution medium to maintain constant volume. The dissolution study was continued for 8 hours to get a simulated picture of the drug release in the *in-vitro* condition and drug dissolved at specified time periods was plotted as percent release versus time (hours) curve.

Analysis of Release Data

The release data obtained were treated according to zero-order (cumulative amount of drug release versus time), first order (log cumulative percentage of drug remaining versus time), Higuchi (cumulative percentage of drug release versus square root of time), and Korsmeyer-Peppas (log cumulative percentage of drug release versus log time) equation models. Dissolution data were also fitted according to the well-known exponential equation, which is often used to describe the drug release behavior from polymeric systems introduced by Korsmeyer-Peppas *et al.* [8].

$$M_t / M_\infty = k t^n$$

Where, M_t is the amount of drug release at time t , M_∞ is the amount of drug release after infinite time; k is a release rate constant incorporating structural and geometric characteristics of the tablet and n is the diffusion exponent indicative of the mechanism of drug release. A value of $n = 0.45$ indicates Fickian (case I) release, > 0.45 but < 0.89 for non-Fickian (anomalous) release and > 0.89 indicates super case II type of release. Case II generally refers to the erosion of the polymeric chain and anomalous

transport (non-Fickian) refers to a combination of both diffusion and erosion controlled-drug release [9].

RESULTS AND DISCUSSION

Drug Content and Physical Evaluation of Ramipril matrix tablets

After preparing the matrix tablets, all the tablets of the proposed formulations were subjected to various evaluation tests such as hardness, thickness, uniformity of weight, drug content and friability (Table 4).

Evaluation of In-Vitro Release

It has been observed that with the decreased amount of the polymer and with the increased amount of lactose, the release of Carvedilol has been increased. The highest release percentage is 63.254% of the F5 formulation containing 10% of METHOCEL K100M CR and highest amount of lactose in 8 hours. On the other hand, the lowest percentage of release is 28.594% containing 30% of METHOCEL K100M CR and lowest amount of lactose in 8 hours. The rate of drug release was found to be inversely related to the amount of METHOCEL K100M CR (Table 5).

The highest METHOCEL K100M CR containing formulation F1 also showed the highest MDT and t_{50} value which indicates the rate retarding effect of METHOCEL K100M CR (Table 6). From Figure 1- 4, we can see the zero order, first order, Higuchi and Korsmeyer-Peppas release kinetics of the formulated drugs respectively.

Table 1. List of active ingredient and other excipients used in the preparation of matrix tablets

Name	Category	Source	Country
Carvedilol	Active ingredient	Silva Pharmaceuticals Ltd	Merck, Germany
Lactose	Filler, Diluent	Colorcon	USA
Mg stearate	Antiadherent	Colorcon	USA
Avicel	Disintegrant	Colorcon	USA
Povidone	Binder	Colorcon	USA
Talc	Lubricant	Colorcon	USA
Methocelk100 MCR	Matrix forming agent	Colorcon	USA

Table 2. List of equipments used in the method of Carvedilol SR tablets

Name	Model	Source	Country
Sieve	-	Endecotts, Test Sieve	UK
Compression Machine	Manesty D type	-	UK
Electronic Balance	AR2140	OHAIS	Switzerland
Digital pH meter	pH 209	HANNA	Romania
Shaker	Power Sonic 505	Hwashin Technology	South Korea
Hardness tester	EH-01P	Electro Lab	India
Fribilator	EF-2	Electro Lab	India
Dissolution Tester	TDT-08L Plus	Electro Lab	India
UV-Spectrophotometer	UV-1800	SHIMADZU Corporation	Japan

Table 3. Different formulation of Carvedilol Sustained Released tablets

Ingredients	F1 mg	F2 mg	F3 mg	F4 mg	F5 mg
Carvedilol	6.25	6.25	6.25	6.25	6.25
Methocel K100MCR	60	54	45	36	27
Lactose	40	55	51.75	57.75	60.75
Mg Stearate	3	2	3	3	3
Avicel	33.50	30	42	30	36
Povidone	35.25	30.75	30	45	45
Talc	2	2	2	2	2

Table 4. Physical properties of Carvedilol matrix tablets containing Methocel K100MCR

Formulation	Weight variation (%) \pm SEM	Hardness (Kf) \pm SEM	Thickness (mm) \pm SEM	Drug content (%)	Friability (%)
F1	997.13 \pm 1.55	6.62 \pm 0.13	3.00 \pm 0.21	99.20	0.88
F2	999.05 \pm 0.35	6.75 \pm 0.17	3.00 \pm 0.22	98.11	0.71
F3	999 \pm 1.27	7.12 \pm 0.18	3.00 \pm 0.16	100.08	0.72
F4	998.12 \pm 3.35	6.80 \pm 0.16	3.50 \pm 0.14	101	0.96
F5	999.25 \pm 2.95	7.05 \pm 0.21	3.00 \pm 0.10	97.72	1.07

Here, n = 10; SEM = Standard Error Mean

Table 5. Percentage of release of the formulated tablet Carvedilol

Time(hr)	F1	F2	F3	F4	F5
0	0	0	0	0	0
1	14.061	17.592	17.985	14.58	26.615
2	15.6365	20.34	20.345	17.592	31.590
3	18.76	23.222	22.44	22.817	37.346
4	20.870	26.363	25.317	29.876	42.586
5	22.835	28.854	27.677	35.774	46.651
6	24.798	32.253	30.814	40.234	51.230
7	26.372	35.787	34.477	49.515	54.901
8	28.594	37.760	45.174	55.413	63.254

Table 6. MDT and t₅₀ value of the drug Carvedilol

Formulation	MDT (hr)	t ₅₀ (hr)
F1	21.65	18.72
F2	16.57	14.23
F3	12.30	11.85
F4	9.12	6.27
F5	5.09	4.50

Figure 1. Zero order release kinetics of Carvedilol from METHOCEL K100MCR matrices




Figure 2. First order release kinetics of Carvedilol from METHOCEL K100MCR matrices






Figure 3. Higuchi release kinetics of Carvedilol from METHOCEL K100MCR matrices**Figure 4. Korsmeyer- Peppas release kinetics of Carvedilol from METHOCEL K100MCR matrices**

CONCLUSION

The study reveals that it is possible to design sustained release drug delivery systems with METHOCEL K100MCR polymer. The polymers which were used in the formulations seem to be satisfactory for sustained release properties. The polymeric effects on the formulated tablets are evident. The MDT and t_{50} value of the formulated tablets were also satisfactory. However, further investigation is required to establish *in-vivo-in-vitro* correlation to reveal the accurate pattern of drug release *in-vivo* environment from this polymeric system.

REFERENCES

1. Alderman DA. A review of cellulose ethers in hydrophilic matrices for oral controlled release dosage form. *International Journal of Pharmaceutical Technology & Product Manufacture*, 5, 1984, 1-9.
2. Lachman L, Liberman HA and Kanig JL. *The Theory and Practice of Industrial Pharmacy*, 3rd ed. Lea & Febiger, Philadelphia, 1986, 430-456.
3. Veiga F, Salsa T, Pina ME. Oral Controlled Release Dosage Forms II glassy polymers in hydrophilic matrices. *Drug Development and Industrial Pharmacy*, 24, 1988, 1-9.
4. Kim H, Fassihi R. Application of binary polymer system in drug release rate modulation. 2. Influence of formulation variables and hydrodynamic conditions on release kinetics. *Journal of Pharmaceutical Sciences*, 86, 1997, 323-328.
5. Williams III RO, Reynolds TD, Cabelka TD, et al. Investigation of excipient type and level on drug release from controlled release tablets containing HPMC. *Pharmaceutical Development and Technology*, 7(2), 2002, 181-193.
6. Chakraverty R. Preparation and evaluation of sustained release microsphere of norfloxacin using sodium alginate. *International Journal Pharmaceutical Sciences and Research*, 3(1), 2011, 293-299.
7. British Pharmacopoeia. Her Majesty's stationary office, London, England. 2, 2000, 266-268.
8. Korsmeyer RW, Gurny R, Peppas NA, et al. Mechanism of solute release from porous hydrophilic polymers. *International Journal of Pharmaceutics*, 15, 1983, 25-35.
9. Shato H, Miyagawa Y, Okabe T, et al. Dissolution mechanism of diclofenac sodium from wax matrix granules. *Journal of Pharmaceutical Sciences*, 86, 1997, 929- 934.

ACKNOWLEDGEMENT

The authors are thankful to the Silva Pharmaceuticals Ltd. for the generous donation of active ingredient of Carvedilol and giving the chance to work in their plant which was very helpful in accomplishing the project work in time and make it successful. The authors are also thankful to all the teachers and staffs of Department of Pharmacy, Noakhali Science and Technology University for their support and cooperation.